Hemp Seed Protein and Bioactive Peptides Consumption for Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Whole hemp seed protein
Whole hemp seed protein plus bioactive peptides
Casein protein
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hemp seed protein, Protein hydrolysate, Bioactive peptides, Cannabis sativa, High blood pressure
Eligibility Criteria
Inclusion Criteria:
- BMI: 18.5-40 kg/m2
- Systolic blood pressure between 130-160 mmHg
- Diastolic blood pressure <100 mmHg
- Ability and willingness to give informed consent to participate in the trial
- Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits
- Willingness to fast 10-12 hours before blood samples and abstain from alcohol two days prior to blood sampling and BP measurement and abstain from coffee and physical exercise at least 14 and 4 hours before measurement respectively
- Negative pregnancy test for women with child-bearing potential
Exclusion Criteria:
- Unable to speak/read in English
- Active cardiovascular disease including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attacks, secondary hypertension, type 1 or type 2 diabetes, anemia, abnormal electrolytes, proteinuria, and abnormal liver, kidney or thyroid function
- History of cancer or malignancy in the last 5 years, or any metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which could interfere with the results of the study or the safety of the participant
- Taking lipid or blood pressure lowering medications or any type of supplements for less than 3 months (Note: all medications or supplements will be permitted if they are on a stable dose for more than 3 months before the start of the study)
- Smokers, tobacco/snuff/nicotine users, recreational drug users
- Consuming more than 14 alcoholic beverages a week
- Any dietary restrictions preventing from consuming the trial treatments
- Weight gain or loss greater than 5 kg in the past three months
- Exercising > 15 miles/wk or 4,000 kcal/wk
- Known to be pregnant or breast-feeding or planning on becoming pregnant during the trial period
- Having clinically significant biochemistry defined as: Sodium: <134 mmol/l, >148 mmol/l; fasting glucose: > 6.1 mmol/L; LDL-C ≥4.9 mmol/L or any other clinically significant abnormality in hematology and/or biochemistry at the investigator's discretion
Sites / Locations
- Richardson Centre for Food Technology and Research
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Whole hemp seed protein
Whole hemp seed protein plus bioactive peptides
Casein protein
Arm Description
25 grams of hemp seed protein powder, twice a day
22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides, twice a day
25 grams of protein powder, twice a day
Outcomes
Primary Outcome Measures
Change in 24 hour ambulatory blood pressure
Participants were fitted with an ambulatory blood pressure monitor (ABPM) for 24 hours. Continuous diastolic and systolic blood pressure were measured over 24 hours.
Secondary Outcome Measures
Change in serum renin
Measured using a fluorometric microplate reader (Spectra MAX Gemini, Molecular Devices, Sunnyvale, CA).
Change in angiotensin-converting enzyme (ACE) activity in the plasma
Measured using spectrophotometric method with furanacryloyl-L-phenylalanylglycylglycine (FAPGG) as substrate
Change in nitric oxide (NO) plasma concentrations
Was determined in plasma using nitrate/nitrite colorimetric assay kit (Cayman Chemical, Michigan, USA)
Change in plasma reactive oxygen and nitrogen species (ROS/RNS)
Was determined using OxiSelec ROS/RNS assay kit and fluorescence plate reader at 480 nm excitation / 530 nm emission
Change in plasma total peroxides (PTPs)
Was determined using microplate reader at 500 nm
Change in plasma superoxide dismutase (SOD)
SOD OxiSelect assay kit (Cell Biolabs, Inc., San Diego, CA, USA) and microplate reader at 490 nm were used for this assay
Change in plasma catalase (CAT)
CAT assay kit (Cell Biolabs, Inc. San Diego, CA, USA) and fluorescence microplate reader at excitation and emission 550 and 590 nm were used for this assay
Full Information
NCT ID
NCT03508895
First Posted
March 29, 2018
Last Updated
December 7, 2022
Sponsor
University of Manitoba
Collaborators
Heart and Stroke Foundation of Canada, Manitoba Harvest
1. Study Identification
Unique Protocol Identification Number
NCT03508895
Brief Title
Hemp Seed Protein and Bioactive Peptides Consumption for Hypertension
Official Title
Double-blind, Randomized, Cross-over Trial of Whole Hemp Seed Protein and Hemp Seed Protein Hydrolysate Derived Bioactive Peptide Consumption for Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
July 16, 2018 (Actual)
Primary Completion Date
November 15, 2019 (Actual)
Study Completion Date
November 15, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Manitoba
Collaborators
Heart and Stroke Foundation of Canada, Manitoba Harvest
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This clinical trial is being conducted to study the effect of whole hemp seed protein, hemp seed protein hydrolysate derived bioactive peptide and casein protein consumption on systolic and diastolic ambulatory blood pressure. This study is will be conducted in 35 hypertensive participants aged between ≥18 and ≤75 yrs who have systolic blood pressure higher than 130 mmHg or diastolic blood pressure ≤ 110 mmHg. The study will consist of 3 periods of 42 days each during which participants will consume assigned treatment. Consumption of treatments will be from days 1 to 42. There will also be a washout period of a minimum of 14 days between the 3 treatment periods where the participants can consume their habitual diets. The entire study is designed to take 22 weeks from start to completion. The participants will consume the assigned treatment twice a day. The treatments are in the form of a smoothie and the smoothies will consist of frozen fruit, fruit juice, frozen yoghurt/sorbet, and 25 g of protein from treatment protein powder which is 25 grams of casein protein, 25 grams of hemp seed protein, or 22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides. On days 1 and 42 of each treatment period of the trial, body weight, waist and hip circumference, blood pressure, pulse wave velocity (PWV) and augmentation index (AI) will be measured. Ambulatory blood pressure (ABP) over 24 hours will also be measured on day 1 of phase 1 and day 42 of each treatment period of the trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hemp seed protein, Protein hydrolysate, Bioactive peptides, Cannabis sativa, High blood pressure
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
31 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Whole hemp seed protein
Arm Type
Experimental
Arm Description
25 grams of hemp seed protein powder, twice a day
Arm Title
Whole hemp seed protein plus bioactive peptides
Arm Type
Experimental
Arm Description
22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides, twice a day
Arm Title
Casein protein
Arm Type
Active Comparator
Arm Description
25 grams of protein powder, twice a day
Intervention Type
Other
Intervention Name(s)
Whole hemp seed protein
Intervention Description
The intervention was provided in the form of a smoothie.
Intervention Type
Other
Intervention Name(s)
Whole hemp seed protein plus bioactive peptides
Intervention Description
The intervention was provided in the form of a smoothie.
Intervention Type
Other
Intervention Name(s)
Casein protein
Intervention Description
The intervention was provided in the form of a smoothie.
Primary Outcome Measure Information:
Title
Change in 24 hour ambulatory blood pressure
Description
Participants were fitted with an ambulatory blood pressure monitor (ABPM) for 24 hours. Continuous diastolic and systolic blood pressure were measured over 24 hours.
Time Frame
Measured at day 1 of phase 1 (baseline) and change from baseline ABP at week 6 of phase 1, 2 and 3
Secondary Outcome Measure Information:
Title
Change in serum renin
Description
Measured using a fluorometric microplate reader (Spectra MAX Gemini, Molecular Devices, Sunnyvale, CA).
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline serum renin at day 42 of phase 1, 2 and 3
Title
Change in angiotensin-converting enzyme (ACE) activity in the plasma
Description
Measured using spectrophotometric method with furanacryloyl-L-phenylalanylglycylglycine (FAPGG) as substrate
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline plasma ACE activity at day 42 of phase 1, 2 and 3
Title
Change in nitric oxide (NO) plasma concentrations
Description
Was determined in plasma using nitrate/nitrite colorimetric assay kit (Cayman Chemical, Michigan, USA)
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline plasma NO concentration at day 42 of phase 1, 2 and 3
Title
Change in plasma reactive oxygen and nitrogen species (ROS/RNS)
Description
Was determined using OxiSelec ROS/RNS assay kit and fluorescence plate reader at 480 nm excitation / 530 nm emission
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline ROS/RNS concentration at day 42 of phase 1, 2 and 3
Title
Change in plasma total peroxides (PTPs)
Description
Was determined using microplate reader at 500 nm
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline PTPs concentration at day 42 of phase 1, 2 and 3
Title
Change in plasma superoxide dismutase (SOD)
Description
SOD OxiSelect assay kit (Cell Biolabs, Inc., San Diego, CA, USA) and microplate reader at 490 nm were used for this assay
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline plasma SOD concentration at day 42 of phase 1, 2 and 3
Title
Change in plasma catalase (CAT)
Description
CAT assay kit (Cell Biolabs, Inc. San Diego, CA, USA) and fluorescence microplate reader at excitation and emission 550 and 590 nm were used for this assay
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline plasma CAT concentration at day 42 of phase 1, 2 and 3
Other Pre-specified Outcome Measures:
Title
Change in blood pressure
Description
Systolic and diastolic blood pressure were measured using an automated oscillometric measurement device in an office setting in a quiet room while the participant wass in a seated position and arm rested on an arm rest at heart level. Participants were advised to rest quietly throughout the measurements. Measurements were performed 4 times at 2-minute intervals.
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline blood pressure at week 3 and 6 of phase 1, 2 and 3
Title
Change in pulse wave velocity (PWV)
Description
Measured using an automated oscillometric measurement device (Mobil-O-Graph, IEM, Stolberg, Germany) in an office setting in a quiet room while the participant was in a seated position and arm rested on an arm rest at heart level. Participants were advised to rest quietly throughout the measurements.
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline PWV at week 6 of phase 1, 2 and 3
Title
Change in augmentation index (AI)
Description
Measured using an automated oscillometric measurement device (Mobil-O-Graph, IEM, Stolberg, Germany) in an office setting in a quiet room while the participant was in a seated position and arm rested on an arm rest at heart level. Participants were advised to rest quietly throughout the measurements.
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline AI at week 6 of phase 1, 2 and 3
Title
Change in body weight
Description
Following standardized procedures
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline body weight at week 6 of phase 1, 2 and 3
Title
Change in waist circumference
Description
Following standardized procedures
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline waist circumference at week 6 of phase 1, 2 and 3
Title
Change in hip circumference
Description
Following standardized procedures
Time Frame
Measured at day 1 of phase 1, 2 and 3 (baseline) and change from baseline hip circumference at week 6 of phase 1, 2 and 3
Title
Change in body composition
Description
Looking at potential changes in body fat and lean mass composition by Dual X-ray absorptiometry (DXA). For this procedure, the participant were needed to lie in a horizontal position for about 5-15 minutes while the scan arm passes from the head to the feet. The radiation from this test was very low dosage (equivalent to approximately 1 day of natural background radiation).
Time Frame
Measured at day 1 of phase 1 (baseline) and change from baseline body composition at week 6 of phase 1, 2 and 3
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
BMI: 18.5-40 kg/m2
Systolic blood pressure between 130-160 mmHg
Diastolic blood pressure ≤ 110 mmHg
Ability and willingness to give informed consent to participate in the trial
Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits
Willingness to fast 10-12 hours before blood samples and abstain from alcohol two days prior to blood sampling and BP measurement and abstain from coffee and physical exercise at least 14 and 4 hours before measurement respectively
Negative pregnancy test for women with child-bearing potential
Exclusion Criteria:
Unable to speak/read in English
Active cardiovascular disease including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attacks, secondary hypertension, type 1 or type 2 diabetes, anemia, abnormal electrolytes, proteinuria, and abnormal liver, kidney or thyroid function
History of cancer or malignancy in the last 5 years, or any metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which could interfere with the results of the study or the safety of the participant
Taking lipid or blood pressure lowering medications or any type of supplements for less than 3 months (Note: all medications or supplements will be permitted if they are on a stable dose for more than 3 months before the start of the study)
Smokers, tobacco/snuff/nicotine users, recreational drug users
Consuming more than 14 alcoholic beverages a week
Any dietary restrictions preventing from consuming the trial treatments
Weight gain or loss greater than 5 kg in the past three months
Exercising > 15 miles/wk or 4,000 kcal/wk
Known to be pregnant or breast-feeding or planning on becoming pregnant during the trial period
Having clinically significant biochemistry defined as: Sodium: <134 mmol/l, >148 mmol/l; fasting glucose: > 6.1 mmol/L; LDL-C ≥4.9 mmol/L or any other clinically significant abnormality in hematology and/or biochemistry at the investigator's discretion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rotimi Aluko, PhD
Organizational Affiliation
University of Manitoba
Official's Role
Principal Investigator
Facility Information:
Facility Name
Richardson Centre for Food Technology and Research
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3T 6C5
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
32326966
Citation
Samsamikor M, Mackay D, Mollard RC, Aluko RE. A double-blind, randomized, crossover trial protocol of whole hemp seed protein and hemp seed protein hydrolysate consumption for hypertension. Trials. 2020 Apr 23;21(1):354. doi: 10.1186/s13063-020-4164-z.
Results Reference
derived
Learn more about this trial
Hemp Seed Protein and Bioactive Peptides Consumption for Hypertension
We'll reach out to this number within 24 hrs